16+
Major trials tracked
Targeted & bispecific oncology · Live ClinicalTrials.gov data
Tarlatamab (Imdelltra) clinical trial pipeline
The timeline below tracks the 16 largest phase 2–4 tarlatamab trials on ClinicalTrials.gov by enrolment, 10 of them actively recruiting. The next phase 3 primary completion among them is expected Jul 2027. Refreshed daily — add up to four competitors to compare pipelines side by side.
6
Phase 3 trials
10
Actively recruiting
Jul 2027
Next phase 3 primary completion
3,244
Participants across trials
Amgen
Lead sponsor by trial count
tarlatamab (16)16 active2021–2039
tarlatamab
'21
'23
'25
'27
'29
'31
'33
'35
'37
'39
tarlatamab
DeLLphi-301P2
DeLLphi-304P3
DeLLphi-306P3
DeLLphi-305P3
DeLLphi-309P2
Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI TreatmentP2
Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)P2
DeLLphi-312P3
Study of How Safe and Effective Tarlatamab is in Brain CancersP2
DeLLightP2
RAGNARP2
TARLANECP3
Tarlatamab for the Treatment of Extensive Stage Small-cell Lung CancerP2
START-lungP2
MERLINP2
PrE0512P3
Upcoming readouts
15 ahead · tarlatamab
Select a trial to load its full ClinicalTrials.gov record.
Key tarlatamab trials
Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07005128 | DeLLphi-312 — A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etopo… | Phase 3 | Recruiting | Jan 2029 |
| NCT06937905 | TARLANEC — Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropa… | Phase 3 | Recruiting | Feb 2029 |
| NCT05740566 | DeLLphi-304 — Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer | Phase 3 | Active, not recruiting | Jan 2025 |
| NCT06211036 | DeLLphi-305 — Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lun… | Phase 3 | Active, not recruiting | Jul 2027 |
| NCT06117774 | DeLLphi-306 — Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) | Phase 3 | Active, not recruiting | Apr 2030 |
| NCT07637513 | PrE0512 — Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Nov 2037 |
| NCT06830694 | Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and … | Phase 2 | Recruiting | Mar 2027 |
| NCT07016230 | Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (… | Phase 2 | Recruiting | Apr 2027 |
| NCT07423585 | Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer | Phase 2 | Recruiting | Dec 2027 |
| NCT06776250 | Study of How Safe and Effective Tarlatamab is in Brain Cancers | Phase 2 | Recruiting | Mar 2028 |
| NCT07061080 | RAGNAR — Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab | Phase 2 | Recruiting | Dec 2028 |
| NCT06893783 | DeLLight — Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients | Phase 2 | Recruiting | Apr 2029 |
Related drug pipelines
FAQ
- How many clinical trials are running for tarlatamab?
- ClinicalTrials.gov lists more than 16 phase 2–4 tarlatamab trials. This page tracks the 16 largest by enrolment: 10 phase 2, 6 phase 3, and 0 phase 4 among them, with 10 actively recruiting. Updated daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare tarlatamab against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.